Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134505 | 1.00 | SIRT2 (0.44) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3891843 | 0.98 | SIRT2 (0.44) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23045026 | 0.95 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5334264 | 0.94 | SIRT2 (0.45) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Phosphoric Acid SCHEMBL28738409 | 0.93 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29544944 | 0.90 | SIRT2 (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL118552 | 0.90 | SIRT2 (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Phosphoric Acid SCHEMBL28738408 | 0.89 | SIRT2 (0.44) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL333397 | 0.89 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Bromide SCHEMBL5514450 | 0.89 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616466-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | Medichem, S.A. (ES) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | claimed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| CN-110891612-A | Conjugates of protein drugs and P/A peptides | XL-蛋白有限责任公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-2468751-B1 | Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM SA (ES) | 2016-03-16 | — | — | EP | disclosed |
| US-8580972-B2 | Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM, S.A. (ES) | 2013-11-12 | — | — | US | disclosed |
| US-20130253187-A1 | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative | MEDICHEM, S.A. (ES) | 2013-09-26 | — | — | US | disclosed |
| US-20120165545-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE | MEDICHEM, S.A. (ES) | 2012-06-28 | — | — | US | disclosed |
| EP-2468751-A2 | Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | Medichem, S.A. (ES) | 2012-06-27 | — | — | EP | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20060089363-A1 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| EP-0443598-B1 | Peptides inhibiting the blood coagulation, their process of preparation and their use | BEHRINGWERKE AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| EP-0443598-A2 | Peptides inhibiting the blood coagulation, their process of preparation and their use | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089363-A1 | Antibacterial agents | ARG1, ALK, ROS1 | SIRT2 3135/4885HDAC3 1267/4885HDAC4 3548/4885 |
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | SIRT2 2449/4885HDAC3 1843/4885HDAC4 1504/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | SIRT2 2465/4885HDAC3 1946/4885HDAC4 1544/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | SIRT2 2465/4885HDAC3 1946/4885HDAC4 1544/4885 |
| US-20130253187-A1 | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative | CYP2C9, CYP3A5, CYP3A43 | SIRT2 546/4885HDAC3 1585/4885HDAC4 3662/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | SIRT2 2449/4885HDAC3 1843/4885HDAC4 1504/4885 |
| US-20120165545-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE | DHPS, CYP3A5, ALKBH5 | SIRT2 2760/4885HDAC3 2033/4885HDAC4 3335/4885 |
| US-20070129310-A1 | Antibacterial agents | ARG1, SCO2, SPOUT1 | SIRT2 2897/4885HDAC3 2312/4885HDAC4 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.